Picture1.png
CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing
16. Dezember 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH has formally filed a petition to have Ms. Alexis Bortell serve as a witness in the upcoming DEA hearing on marijuana rescheduling.
Picture1.png
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip
25. November 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
our Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuv
Picture1.png
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
01. Juli 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatm
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
26. Juni 2024 10:52 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's distributor
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
17. Juni 2024 09:50 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation.
Relevium_LOGO_200.jpg
Relevium Ships First Purchase Order Release of $130,000 to Middle East Customer
03. März 2020 11:45 ET | Relevium Technologies Inc
MONTREAL, March 03, 2020 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the Company’s...
Relevium_LOGO_200.jpg
Relevium Reports Improved Financial Results for Second Quarter of Fiscal 2020  
02. März 2020 08:30 ET | Relevium Technologies Inc
MONTREAL, March 02, 2020 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results...
Relevium_LOGO_200.jpg
Relevium Launches LeefyLyfe™ Organic Hemp Products in the US
20. November 2019 09:18 ET | Relevium Technologies Inc
MONTREAL, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the launch of...
Relevium_LOGO_200.jpg
Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company
08. November 2019 08:35 ET | Relevium Technologies Inc
MONTREAL, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a...
Relevium_LOGO_200.jpg
Relevium’s Subsidiary BGX E-Health Secures One Million Dollar Export Contract for the Middle East
30. Oktober 2019 09:30 ET | Relevium Technologies Inc
MONTREAL, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned...